Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03470480 · ClinicalTrials.gov registry record · NA
rTMS for Craving in Methamphetamine Use Disorder
A NA study of Substance Use Disorders and Methamphetamine-dependence, sponsored by Oregon Health and Science University.
- Recruiting
- Registry status
- NA
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT03470480: Recruiting NA study of Substance Use Disorders and Methamphetamine-dependence, sponsored by Oregon Health and Science University.
NCT03470480 is a NA study of Substance Use Disorders and Methamphetamine-dependence that is actively recruiting participants, run by Oregon Health and Science University. The registered enrollment target is 50 participants, below the 500-participant average among 93 other Substance Use Disorders trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03470480, a NA study of Substance Use Disorders and Methamphetamine-dependence, is actively recruiting participants, sponsored by Oregon Health and Science University.
- RECRUITING
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary aim of this project is to use a randomized single-blind sham-controlled study to investigate if high frequency repetitive transmagnetic stimulation (HF-rTMS) can modulate cue-induced craving in adult methamphetamine (METH) users. The investigators hypothesize that HF-rTMS directed at left dorsolateral prefrontal cortex (DLPFC) will result in a reduction in craving for METH compared to sham-controlled rTMS in adults with methamphetamine use disorder (MUD) as evidenced by validated measures of METH craving. Neurobiologically, the investigators anticipate rTMS mediated stimulation of the DLPFC could result in inhibition of cue-induced craving through potential disruption of involved circuitry. The current project proposes that participants who are recently abstinent from METH will be randomized into four experimental groups to provide two rTMS conditions (real versus sham) and two picture cues conditions (METH versus neutral). The experiment will have an induction phase where each subject will receive 10 daily treatments within 2 weeks. Just before each rTMS/sham session participants will be shown visual cues (METH or neutral). Participants will then undergo a maintenance phase for an additional month with assessments to evaluate craving and relapse. Urine samples for urine drug screening (UDS) will be collected at screening day and on days 1, 5 and 10. Just before each rTMS/sham session participants will be shown visual cues (METH and neutral). VAS craving scores will be assessed before and after picture presentation and after the rTMS/sham session. Before the first and 10th treatment session, participants were evaluated by the the Stimulant Craving Questionnaire (STCQ) and the Severity of Dependence Scale (SDS) questionnaires. Participants will then undergo a maintenance phase for an additional month. During the first week of maintenance, three rTMS/sham sessions will be administered. During each of the following 3 weeks, one rTMS/sham session will be giv
Conditions Studied
Interventions
- DEVICE Real Repetitive transcranial magnetic stimulation
- DEVICE Sham Repetitive transcranial magnetic stimulation
- BEHAVIORAL Methamphetamine visual cues
- BEHAVIORAL Neutral visual cues
Study Locations (1)
Oregon
- Veterans Affairs Portland Health Care System - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2018-02-07 |
| Est. Completion | 2025-09-01 |
| Phase | NA |
What NCT03470480 shows while recruiting
NCT03470480 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 500-participant average among 93 other Substance Use Disorders trials with a reported enrollment target (90% lower).
The record links to 6 conditions, with Substance Use Disorders appearing as the primary indexed condition, and to 4 interventions - of which Real Repetitive transcranial magnetic stimulation is the first listed.
NCT03470480 reports a single indexed study location in Oregon.
Frequently Asked Questions
What is clinical trial NCT03470480 about?
NCT03470480 is a clinical study titled "rTMS for Craving in Methamphetamine Use Disorder". The primary aim of this project is to use a randomized single-blind sham-controlled study to investigate if high frequency repetitive transmagnetic stimulation (HF-rTMS) can modulate cue-induced craving in adult methamphetamine (METH) users. The investigators hypothesize that HF-rTMS directed at lef...
What is the current status of trial NCT03470480?
This trial is currently recruiting. It is a NA study. The enrollment target is 50 participants. The study started on 2018-02-07. Estimated completion is 2025-09-01.
What conditions does trial NCT03470480 study?
This clinical trial studies the following conditions: Substance Use Disorders, Methamphetamine-dependence, Methamphetamine Abuse, Transcranial Magnetic Stimulation, Stimulant Use.
What interventions are being tested in trial NCT03470480?
The interventions under investigation include: Real Repetitive transcranial magnetic stimulation (DEVICE), Sham Repetitive transcranial magnetic stimulation (DEVICE), Methamphetamine visual cues (BEHAVIORAL), Neutral visual cues (BEHAVIORAL).
Who is sponsoring clinical trial NCT03470480?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03470480 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Substance Use Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03470480's enrollment target sits among peer trials
50 69th of 93 higher than 21 of 93 other Substance Use Disorders trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Substance Use Disorders trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Supporting Treatment Access and Recovery Through Linkage and Support
RECRUITING · NA
-
Development OF A Novel Peer Recovery Supporter Training Platform
RECRUITING · NA
-
Project I Test: Implementing HIV Testing in Opioid Treatment Programs
RECRUITING · NA
-
Testing Strategies to Improve Substance Misuse Prevention Research Use in State Policy Contexts
RECRUITING · NA
-
Families Left Behind
RECRUITING · NA
-
Trauma Screening/Referral and Interpersonal Violence Prevention for Women with Substance Use Disorders
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI